ClinicalTrials.gg
CompletedNCT01872689Updated Aug 24, 2018Results posted

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of Lebrikizumab and Pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by Hoffmann-La Roche. Completed at 112 sites in 13 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-08-24.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
505
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.

Enrollment
5th of 21
505 · median 89
Started
2013
the only one that year
Phase 2
6 of 21
none open now
Registered
7th of 21
by date
Lead sponsor
4 of 21
Hoffmann-La Roche

Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 2, and was the 7th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy and as combination therapy with pirfenidone background therapy in participants with IPF. Participants will be randomized to receive either lebrikizumab or placebo subcutaneously every 4 weeks.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Have a diagnosis of IPF within the previous 5 years from time of screening and confirmed at baseline
  • FVC >/=40 percent (%) and \</=100% of predicted at screening
  • Stable baseline lung function as evidenced by a difference of less than (\<) 10% in FVC (in liters) measurements between screening and Day 1, Visit 2 prior to randomization
  • DLco >/=25% and \</=90% of predicted at screening
  • Ability to walk >/=100 meters unassisted in 6 minutes
  • Cohort A: No background IPF therapy for >/=4 weeks allowed prior to randomization and throughout the placebo-controlled study period
  • Cohort B: Tolerated dose of pirfenidone \</=2403 milligrams once daily (mg/day) for >/=4 weeks required prior to randomization and throughout the placebo-controlled study period

Exclusion Criteria:

  • History of severe allergic reaction or anaphylactic reaction to a biologic agent or known to any component of the lebrikizumab injection
  • Evidence of other known causes of interstitial lung disease
  • Lung transplant expected within 12 months of screening
  • Evidence of lung disease other than IPF
  • Post-bronchodilator (FEV1)/FVC ratio \<0.7 at screening
  • Positive bronchodilator response, evidenced by an increase of >/=12% predicted and 200 milliliters increase in FEV1 or FVC
  • Class IV chronic heart failure or historical evidence of \<35%
  • Hospitalization due to an exacerbation of IPF within 4 weeks prior to or during screening
  • Known current or current evaluation for potential malignancy
  • Listeria monocytogenes infection or active parasitic infection within 6 months prior to Day 1, Visit 2
  • Active tuberculosis requiring treatment within 12 months of screening
  • Known immunodeficiency, including but not limited to infection
  • Past use of any anti-interleukin (IL)-13 or anti-IL-4/IL-13 therapy, including lebrikizumab
  • Evidence of acute or chronic hepatitis or known liver cirrhosis

Exclusions Criteria Limited to Cohort B:

  • Known achalasia, esophageal stricture, or esophageal dysfunction sufficient to limit the ability to swallow oral medication
  • Tobacco smoking or use of tobacco-related products within 3 months of screening or unwillingness to avoid smoking throughout the study period
  • Known or suspected peptic ulcer
  • Any condition that, as assessed by the investigator, might be significantly exacerbated by the known side effects associated with pirfenidone
  • \<40 milliliters/minute, calculated using the Cockcroft-Gault formula
  • Use of following therapies within 4 weeks of randomization (Day 1, Visit 2) or during the study: Strong inhibitors of CYP1A2 (Cytochrome P450 Family 1 Subfamily A Member 2) (example: fluvoxamine or enoxacin); Moderate inducers of CYP1A2 (limited to tobacco smoking and tobacco-related products)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
505 participants (actual)

Study arms

  • Placebo comparator
    Monotherapy (Cohort A): Placebo

    Participants will receive monotherapy with placebo matched to lebrikizumab administered via subcutaneous (SC) injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.

    Drug: Lebrikizumab · Drug: Placebo

  • Experimental
    Monotherapy (Cohort A): Lebrikizumab

    Participants will receive monotherapy with lebrikizumab at a dose of 250 milligrams (mg) administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.

    Drug: Lebrikizumab

  • Placebo comparator
    Combination Therapy (Cohort B): Placebo + Pirfenidone

    Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day \[9 capsules daily\] for a total of 2403 mg/day) or at maximum tolerated dose (MTD) administered orally along with placebo matched to lebrikizumab administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.

    Drug: Pirfenidone · Drug: Placebo

  • Experimental
    Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone

    Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day \[9 capsules daily\] for a total of 2403 mg/day) or at MTD administered orally along with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.

    Drug: Lebrikizumab · Drug: Pirfenidone

Interventions

  • Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.

    Also known as: RO5490255

  • Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.

  • DrugPlacebo

    Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Decrease in Percent Predicted Forced Vital Capacity (FVC) Over 52 Weeks

    Annualized rates of decrease (slope throughout time from baseline to Week 52) for percent predicted FVC was assessed and reported. FVC is a standard pulmonary function test. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.

    Time frame: Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)

Secondary outcomes

  1. Annualized Rate of Decline in 6-Minute Walk Test (6MWT) Distance Over 52 Weeks

    Annualized rates of decline (slope throughout time from baseline to Week 52) in 6MWT was assessed and reported. 6MWT was the distance (in meters \[m\]) that a participant could walk in 6 minutes.

    Time frame: Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)

  2. Percentage of Participants With Event of Greater Than or Equal to (>/=) 10% Absolute Decline in Percent Predicted FVC or Death From Any Cause

    FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.

    Time frame: Baseline up to the event of >/=10% absolute decline in percent predicted FVC or death from any cause, whichever occurred first (up to Week 122)

  3. Time to First Occurrence of a >/=10% Absolute Decline in Percent Predicted FVC or Death From Any Cause

    FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100. Time from randomization to first occurrence of an event of \>/=10% absolute decline in percent predicted FVC or death from any cause was reported. Participants without an event were censored at the last assessment during the double-blind treatment period. Any participant who underwent lung transplantation was censored at the date of the transplant. The median time to event was estimated using Kaplan-Meier method. 95% confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Baseline up to the event of >/=10% absolute decline in percent predicted FVC or death from any cause, whichever occurred first (up to Week 122)

  4. Annualized Rate of Decrease in Diffusion Capacity of the Lung for Carbon Monoxide (DLco) Over 52 Weeks

    Annualized rates of decrease (slope throughout time from baseline to Week 52) in DLco was assessed and reported. DLco (in milliliters per minute/millimeters of mercury \[mL/min/mmHg\]) is a measure of the gas transfer.

    Time frame: Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)

  5. Percentage of Participants With Event of Death, All Cause Hospitalization, or a Decrease From Baseline of >/=10% in FVC

    FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC = \[(observed FVC)/(predicted FVC)\]\*100.

    Time frame: Baseline up to the event of death from any cause, all cause hospitalization, or a decrease from baseline of >/=10% in FVC, whichever occurred first (up to Week 122)

  6. Progression-Free Survival (PFS)

    FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC = \[(observed FVC)/(predicted FVC)\]\*100. PFS was defined as time from randomization to death from any cause, all cause hospitalization, or a decrease from baseline of \>/=10% in FVC, whichever occurred first. Participants without an event were censored at the last assessment during the double-blind treatment period. Any participant who underwent lung transplantation was censored at the date of the transplant. The median PFS was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Baseline up to the event of death from any cause, all cause hospitalization, or a decrease from baseline of >/=10% in FVC, whichever occurred first (up to Week 122)

  7. Annualized Rate of Decrease in FVC Over 52 Weeks

    Annualized rates of decrease (slope throughout time from baseline to Week 52) in FVC (in milliliters per year \[mL/year\]) was assessed and reported. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position.

    Time frame: Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)

  8. Annualized Rate of Decrease in A Tool to Assess Quality of Life in IPF (ATAQ-IPF) Questionnaire Total Score Over 52 Weeks

    The ATAQ-IPF Version 3 was utilized that included 31 items within 5 domains: cough (6 items), dyspnea (7 items), exhaustion (6 items), emotional well-being (6 items), and independence (6 items). Each item was assessed on a scale ranging from 1 (Strongly disagree) to 4 (Strongly agree). The ATAQ-IPF had a recall specification of 2 weeks. Simple summation scoring was used to derive individual domain scores as well as a total score. ATAQ-IPF total score ranged from 31 to 124 with lower score indicating better quality of life (QoL). Annualized rates of decrease (slope throughout time from baseline to Week 52) in ATAQ-IPF questionnaire total score was assessed and reported.

    Time frame: Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)

  9. Percentage of Participants With an Event of St. George's Respiratory Questionnaire (SGRQ) Total Score Worsening or Death From Any Cause

    The SGRQ is a 50-item health-related QoL instrument that measured health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. The SGRQ had a recall specification of 4 weeks. The SGRQ total score (summed weights) ranged from 0 to 100 with a lower score denoting a better health status. Percentage of participants with an event of SGRQ total score worsening (defined as reaching minimal important difference \[MID\], that is, an increase in total score of \>/=7) or death from any cause was reported.

    Time frame: Baseline up to the event of SGRQ total score worsening or death from any cause, whichever occurred first (up to Week 122)

  10. Time to First Occurrence of SGRQ Total Score Worsening or Death From Any Cause

    The SGRQ is a 50-item health-related QoL instrument that measured health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. The SGRQ had a recall specification of 4 weeks. The SGRQ total score (summed weights) ranged from 0 to 100 with a lower score denoting a better health status. Time from randomization to first occurrence of an event of SGRQ total score worsening (defined as reaching minimal important difference \[MID\], that is, an increase in total score of \>/=7) or death from any cause was reported. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Baseline up to the event of SGRQ total score worsening or death from any cause, whichever occurred first (up to Week 122)

  11. Percentage of Participants With an Event of Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

    IPF exacerbation was defined as an event that met all of the following criteria as determined by the investigator: Unexplained worsening or development of dyspnea within the previous 30 days; And radiologic evidence of new bilateral ground-glass abnormality or consolidation, superimposed on a reticular or honeycomb background pattern, that is consistent with usual interstitial pneumonitis; And absence of alternative causes, such as left heart failure, pulmonary embolism, pulmonary infection (on the basis of endotracheal aspirate or bronchoalveolar lavage if available, or investigator judgment), or other events leading to acute lung injury (for example, sepsis, aspiration, trauma, reperfusion pulmonary edema).

    Time frame: Baseline up to the event of acute IPF exacerbation (up to Week 122)

  12. Time to First Event of Acute IPF Exacerbation

    Time from randomization to first occurrence of an event of IPF exacerbation was reported. IPF exacerbation was defined as an event that met all of the following criteria as determined by the investigator: Unexplained worsening or development of dyspnea within the previous 30 days; And radiologic evidence of new bilateral ground-glass abnormality or consolidation, superimposed on a reticular or honeycomb background pattern, that is consistent with usual interstitial pneumonitis; And absence of alternative causes, or other events leading to acute lung injury. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Baseline up to the event of acute IPF exacerbation (up to Week 122)

  13. Percentage of Participants With Respiratory-Related Hospitalization

    Time frame: Baseline up to the event of respiratory-related hospitalization (up to Week 122)

  14. Time to Respiratory-Related Hospitalization

    Time from randomization to first occurrence of an event of respiratory-related hospitalization was reported. Participants without an event were censored at the last known alive day, study Day 368, or the last date during the double-blind period. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Baseline up to the event of respiratory-related hospitalization (up to Week 122)

  15. Percentage of Participants With an Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause

    DLco (in mL/min/mmHg) is a measure of the gas transfer. Predicted DLco is based on sex, age, and height of a person. Percent of predicted DLco (in %) = \[(observed DLco)/(predicted DLco)\]\*100.

    Time frame: Baseline up to the event of >/=15% absolute decrease in percentage of predicted DLco or death from any cause (up to Week 122)

  16. Time to First Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause

    DLco is a measure of the gas transfer. Predicted DLco is based on sex, age, and height of a person. Percent of predicted DLco (in %) = \[(observed DLco)/(predicted DLco)\]\*100. Time from randomization to first occurrence of \>/=15% absolute decrease in percentage of predicted DLco or death from any cause was reported. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Baseline up to the event of >/=15% absolute decrease in percentage of predicted DLco or death from any cause (up to Week 122)

  17. Percentage of Participants With Anti-therapeutic Antibody (ATA) to Lebrikizumab

    ATA to lebrikizumab was tested using a validated immunoassay. A positive ATA result was defined as one in which the presence of detectable ATAs could be confirmed by competitive binding with lebrikizumab. Percentage of participants with positive results for ATA at Baseline and at post-baseline time points were reported. Only participants who received lebrikizumab were included in the analysis.

    Time frame: Baseline and Post-Baseline (assessed at multiple time points: Weeks 4, 12, 24, 36, 52, 56, 64, 76, and at safety follow-up up to Week 122)

  18. Minimum Observed Serum Concentration (Cmin) of Lebrikizumab at Week 52

    Participants who received lebrikizumab were only included in the analysis.

    Time frame: Predose (Hour 0) at Week 52

  19. Minimum Observed Serum Concentration (Cmin) of Lebrikizumab

    Participants who received lebrikizumab were only included in the analysis.

    Time frame: Predose (Hour 0) at Weeks 4, 12, 24, and 36

  20. Elimination Half-Life (t1/2) of Lebrikizumab

    Elimination half-life is the time measured for the plasma drug concentration to decrease by one-half during the elimination phase of the drug. Analysis was performed on PK-Evaluable Population. Participants who received lebrikizumab were only included in the analysis.

    Time frame: Pre-dose (Hour 0) at Weeks 1, 4, 12, 24, 36, 64, 76, 88, 104; and at 4, 12, and 18 weeks post-last dose (last dose = Week 104)

07

Results

Posted Aug 24, 2018

Participant flow

Double-Blind/Placebo-Controlled Period
Participant flow — Double-Blind/Placebo-Controlled Period
MilestoneMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Started7678177174
Completed5658129136
Not completed20204838
Withdrew: Lack of efficacy0100
Withdrew: Other1163
Withdrew: Withdrawal by subject981416
Withdrew: Protocol violation0011
Withdrew: Physician decision0331
Withdrew: Lost to follow-up1001
Withdrew: Death34149
Withdrew: Adverse event63107
Open-Label Period (Only For Monotherapy)
Participant flow — Open-Label Period (Only For Monotherapy)
MilestoneMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Started525600
Completed313300
Not completed212300
Withdrew: Other2300
Withdrew: Withdrawal by subject111200
Withdrew: Physician decision0100
Withdrew: Lost to follow-up1300
Withdrew: Death5300
Withdrew: Adverse event2100

Outcome measures

PrimaryAnnualized Rate of Decrease in Percent Predicted Forced Vital Capacity (FVC) Over 52 Weeks

Annualized rates of decrease (slope throughout time from baseline to Week 52) for percent predicted FVC was assessed and reported. FVC is a standard pulmonary function test. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.

Time frame:
Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Reported as:
Mean · percent predicted FVC/year
Annualized Rate of Decrease in Percent Predicted Forced Vital Capacity (FVC) Over 52 Weeks
percent predicted FVC/yearMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Annualized Rate of Decrease in Percent Predicted Forced Vital Capacity (FVC) Over 52 Weeks-6.1876 ± 0.92597-5.2065 ± 0.92758-6.0430 ± 0.60633-5.5430 ± 0.59507
Statistical analysis
  • Monotherapy (Cohort A): Placebo vs Monotherapy (Cohort A): Lebrikizumab · Mixed Models Analysis · p = 0.4555 · Median difference (final values): 0.98111 · 95% CI -1.61 to 3.57
  • Combination Therapy (Cohort B): Placebo + Pirfenidone vs Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone · Mixed Models Analysis · p = 0.5566 · Mean difference (final values): 0.49998 · 95% CI -1.17 to 2.17
SecondaryAnnualized Rate of Decline in 6-Minute Walk Test (6MWT) Distance Over 52 Weeks

Annualized rates of decline (slope throughout time from baseline to Week 52) in 6MWT was assessed and reported. 6MWT was the distance (in meters \[m\]) that a participant could walk in 6 minutes.

Time frame:
Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Reported as:
Mean · m/year
Annualized Rate of Decline in 6-Minute Walk Test (6MWT) Distance Over 52 Weeks
m/yearMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Annualized Rate of Decline in 6-Minute Walk Test (6MWT) Distance Over 52 Weeks-44.6512 ± 15.97862-22.7209 ± 15.34753-25.5683 ± 12.24923-46.9810 ± 11.84199
Statistical analysis
  • Monotherapy (Cohort A): Placebo vs Monotherapy (Cohort A): Lebrikizumab · Mixed Models Analysis · p = 0.3129 · Median difference (final values): 21.93023 · 95% CI -20.97 to 64.83
  • Combination Therapy (Cohort B): Placebo + Pirfenidone vs Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone · Mixed Models Analysis · p = 0.2036 · Mean difference (final values): -21.4127 · 95% CI -54.50 to 11.67
SecondaryPercentage of Participants With Event of Greater Than or Equal to (>/=) 10% Absolute Decline in Percent Predicted FVC or Death From Any Cause

FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.

Time frame:
Baseline up to the event of >/=10% absolute decline in percent predicted FVC or death from any cause, whichever occurred first (up to Week 122)
Reported as:
Number · percentage of participants
Percentage of Participants With Event of Greater Than or Equal to (>/=) 10% Absolute Decline in Percent Predicted FVC or Death From Any Cause
percentage of participantsMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Percentage of Participants With Event of Greater Than or Equal to (>/=) 10% Absolute Decline in Percent Predicted FVC or Death From Any Cause34.227.630.326.6
SecondaryTime to First Occurrence of a >/=10% Absolute Decline in Percent Predicted FVC or Death From Any Cause

FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100. Time from randomization to first occurrence of an event of \>/=10% absolute decline in percent predicted FVC or death from any cause was reported. Participants without an event were censored at the last assessment during the double-blind treatment period. Any participant who underwent lung transplantation was censored at the date of the transplant. The median time to event was estimated using Kaplan-Meier method. 95% confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Baseline up to the event of >/=10% absolute decline in percent predicted FVC or death from any cause, whichever occurred first (up to Week 122)
Reported as:
Median · weeks
Time to First Occurrence of a >/=10% Absolute Decline in Percent Predicted FVC or Death From Any Cause
weeksMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Time to First Occurrence of a >/=10% Absolute Decline in Percent Predicted FVC or Death From Any Cause53.1 (52.6 to NA)NA (NA to NA)NA (52.9 to NA)NA (NA to NA)
Statistical analysis
  • Monotherapy (Cohort A): Placebo vs Monotherapy (Cohort A): Lebrikizumab · Log Rank · p = 0.4299 · Hazard ratio (hr): 0.79 · 95% CI 0.44 to 1.41
  • Combination Therapy (Cohort B): Placebo + Pirfenidone vs Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone · Log Rank · p = 0.3751 · Hazard ratio (hr): 0.84 · 95% CI 0.56 to 1.24
SecondaryAnnualized Rate of Decrease in Diffusion Capacity of the Lung for Carbon Monoxide (DLco) Over 52 Weeks

Annualized rates of decrease (slope throughout time from baseline to Week 52) in DLco was assessed and reported. DLco (in milliliters per minute/millimeters of mercury \[mL/min/mmHg\]) is a measure of the gas transfer.

Time frame:
Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Reported as:
Mean · mL/min/mmHg/year
Annualized Rate of Decrease in Diffusion Capacity of the Lung for Carbon Monoxide (DLco) Over 52 Weeks
mL/min/mmHg/yearMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Annualized Rate of Decrease in Diffusion Capacity of the Lung for Carbon Monoxide (DLco) Over 52 Weeks-4.7818 ± 0.74479-4.2400 ± 0.73826-5.7552 ± 0.46561-5.5732 ± 0.45577
Statistical analysis
  • Monotherapy (Cohort A): Placebo vs Monotherapy (Cohort A): Lebrikizumab · Mixed Models Analysis · p = 0.6075 · Median difference (final values): 0.54171 · 95% CI -1.54 to 2.62
  • Combination Therapy (Cohort B): Placebo + Pirfenidone vs Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone · Mixed Models Analysis · p = 0.7803 · Mean difference (final values): 0.18203 · 95% CI -1.10 to 1.47
SecondaryPercentage of Participants With Event of Death, All Cause Hospitalization, or a Decrease From Baseline of >/=10% in FVC

FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC = \[(observed FVC)/(predicted FVC)\]\*100.

Time frame:
Baseline up to the event of death from any cause, all cause hospitalization, or a decrease from baseline of >/=10% in FVC, whichever occurred first (up to Week 122)
Reported as:
Number · percentage of participants
Percentage of Participants With Event of Death, All Cause Hospitalization, or a Decrease From Baseline of >/=10% in FVC
percentage of participantsMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Percentage of Participants With Event of Death, All Cause Hospitalization, or a Decrease From Baseline of >/=10% in FVC47.432.939.439.9
SecondaryProgression-Free Survival (PFS)

FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC = \[(observed FVC)/(predicted FVC)\]\*100. PFS was defined as time from randomization to death from any cause, all cause hospitalization, or a decrease from baseline of \>/=10% in FVC, whichever occurred first. Participants without an event were censored at the last assessment during the double-blind treatment period. Any participant who underwent lung transplantation was censored at the date of the transplant. The median PFS was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Baseline up to the event of death from any cause, all cause hospitalization, or a decrease from baseline of >/=10% in FVC, whichever occurred first (up to Week 122)
Reported as:
Median · weeks
Progression-Free Survival (PFS)
weeksMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Progression-Free Survival (PFS)52.6 (43.9 to NA)NA (NA to NA)NA (NA to NA)NA (52.3 to NA)
Statistical analysis
  • Monotherapy (Cohort A): Placebo vs Monotherapy (Cohort A): Lebrikizumab · Log Rank · p = 0.0972 · Hazard ratio (hr): 0.65 · 95% CI 0.39 to 1.09
  • Combination Therapy (Cohort B): Placebo + Pirfenidone vs Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone · Log Rank · p = 0.9344 · Hazard ratio (hr): 1.01 · 95% CI 0.72 to 1.42
SecondaryAnnualized Rate of Decrease in FVC Over 52 Weeks

Annualized rates of decrease (slope throughout time from baseline to Week 52) in FVC (in milliliters per year \[mL/year\]) was assessed and reported. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position.

Time frame:
Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Reported as:
Mean · mL/year
Annualized Rate of Decrease in FVC Over 52 Weeks
mL/yearMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Annualized Rate of Decrease in FVC Over 52 Weeks-221.029 ± 34.87511-192.906 ± 34.93853-231.167 ± 22.67786-209.437 ± 22.25073
Statistical analysis
  • Monotherapy (Cohort A): Placebo vs Monotherapy (Cohort A): Lebrikizumab · Mixed Models Analysis · p = 0.5707 · Median difference (final values): 28.12302 · 95% CI -69.80 to 126.04Mean Difference = Lebrikizumab - Placebo
  • Combination Therapy (Cohort B): Placebo + Pirfenidone vs Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone · Mixed Models Analysis · p = 0.4934 · Mean difference (final values): 21.72972 · 95% CI -40.65 to 84.11Mean Difference = Lebrikizumab - Placebo
SecondaryAnnualized Rate of Decrease in A Tool to Assess Quality of Life in IPF (ATAQ-IPF) Questionnaire Total Score Over 52 Weeks

The ATAQ-IPF Version 3 was utilized that included 31 items within 5 domains: cough (6 items), dyspnea (7 items), exhaustion (6 items), emotional well-being (6 items), and independence (6 items). Each item was assessed on a scale ranging from 1 (Strongly disagree) to 4 (Strongly agree). The ATAQ-IPF had a recall specification of 2 weeks. Simple summation scoring was used to derive individual domain scores as well as a total score. ATAQ-IPF total score ranged from 31 to 124 with lower score indicating better quality of life (QoL). Annualized rates of decrease (slope throughout time from baseline to Week 52) in ATAQ-IPF questionnaire total score was assessed and reported.

Time frame:
Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Reported as:
Mean · units on a scale/year
Annualized Rate of Decrease in A Tool to Assess Quality of Life in IPF (ATAQ-IPF) Questionnaire Total Score Over 52 Weeks
units on a scale/yearMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Annualized Rate of Decrease in A Tool to Assess Quality of Life in IPF (ATAQ-IPF) Questionnaire Total Score Over 52 Weeks6.8907 ± 1.717784.7886 ± 1.703705.6189 ± 0.998805.4558 ± 0.97793
Statistical analysis
  • Monotherapy (Cohort A): Placebo vs Monotherapy (Cohort A): Lebrikizumab · Mixed Models Analysis · p = 0.3854 · Median difference (final values): -2.10204 · 95% CI -6.88 to 2.68
  • Combination Therapy (Cohort B): Placebo + Pirfenidone vs Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone · Mixed Models Analysis · p = 0.9057 · Mean difference (final values): -0.16313 · 95% CI -2.87 to 2.55
SecondaryPercentage of Participants With an Event of St. George's Respiratory Questionnaire (SGRQ) Total Score Worsening or Death From Any Cause

The SGRQ is a 50-item health-related QoL instrument that measured health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. The SGRQ had a recall specification of 4 weeks. The SGRQ total score (summed weights) ranged from 0 to 100 with a lower score denoting a better health status. Percentage of participants with an event of SGRQ total score worsening (defined as reaching minimal important difference \[MID\], that is, an increase in total score of \>/=7) or death from any cause was reported.

Time frame:
Baseline up to the event of SGRQ total score worsening or death from any cause, whichever occurred first (up to Week 122)
Reported as:
Number · percentage of participants
Percentage of Participants With an Event of St. George's Respiratory Questionnaire (SGRQ) Total Score Worsening or Death From Any Cause
percentage of participantsMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): Lebrikizumab
Percentage of Participants With an Event of St. George's Respiratory Questionnaire (SGRQ) Total Score Worsening or Death From Any Cause57.948.7
SecondaryTime to First Occurrence of SGRQ Total Score Worsening or Death From Any Cause

The SGRQ is a 50-item health-related QoL instrument that measured health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. The SGRQ had a recall specification of 4 weeks. The SGRQ total score (summed weights) ranged from 0 to 100 with a lower score denoting a better health status. Time from randomization to first occurrence of an event of SGRQ total score worsening (defined as reaching minimal important difference \[MID\], that is, an increase in total score of \>/=7) or death from any cause was reported. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Baseline up to the event of SGRQ total score worsening or death from any cause, whichever occurred first (up to Week 122)
Reported as:
Median · weeks
Time to First Occurrence of SGRQ Total Score Worsening or Death From Any Cause
weeksMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): Lebrikizumab
Time to First Occurrence of SGRQ Total Score Worsening or Death From Any Cause51.7 (24.1 to 54.6)52.3 (35.7 to NA)
Statistical analysis
  • Monotherapy (Cohort A): Placebo vs Monotherapy (Cohort A): Lebrikizumab · Log Rank · p = 0.4433 · Hazard ratio (hr): 0.84 · 95% CI 0.54 to 1.31
SecondaryPercentage of Participants With an Event of Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

IPF exacerbation was defined as an event that met all of the following criteria as determined by the investigator: Unexplained worsening or development of dyspnea within the previous 30 days; And radiologic evidence of new bilateral ground-glass abnormality or consolidation, superimposed on a reticular or honeycomb background pattern, that is consistent with usual interstitial pneumonitis; And absence of alternative causes, such as left heart failure, pulmonary embolism, pulmonary infection (on the basis of endotracheal aspirate or bronchoalveolar lavage if available, or investigator judgment), or other events leading to acute lung injury (for example, sepsis, aspiration, trauma, reperfusion pulmonary edema).

Time frame:
Baseline up to the event of acute IPF exacerbation (up to Week 122)
Reported as:
Number · percentage of participants
Percentage of Participants With an Event of Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
percentage of participantsMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Percentage of Participants With an Event of Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation3.93.96.32.9
SecondaryTime to First Event of Acute IPF Exacerbation

Time from randomization to first occurrence of an event of IPF exacerbation was reported. IPF exacerbation was defined as an event that met all of the following criteria as determined by the investigator: Unexplained worsening or development of dyspnea within the previous 30 days; And radiologic evidence of new bilateral ground-glass abnormality or consolidation, superimposed on a reticular or honeycomb background pattern, that is consistent with usual interstitial pneumonitis; And absence of alternative causes, or other events leading to acute lung injury. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Baseline up to the event of acute IPF exacerbation (up to Week 122)
Reported as:
Median · weeks
Time to First Event of Acute IPF Exacerbation
weeksMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Time to First Event of Acute IPF ExacerbationNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Monotherapy (Cohort A): Placebo vs Monotherapy (Cohort A): Lebrikizumab · Log Rank · p = 0.9366 · Hazard ratio (hr): 1.07 · 95% CI 0.21 to 5.30
  • Combination Therapy (Cohort B): Placebo + Pirfenidone vs Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone · Log Rank · p = 0.1346 · Hazard ratio (hr): 0.45 · 95% CI 0.16 to 1.31
SecondaryPercentage of Participants With Respiratory-Related Hospitalization
Time frame:
Baseline up to the event of respiratory-related hospitalization (up to Week 122)
Reported as:
Number · percentage of participants
Percentage of Participants With Respiratory-Related Hospitalization
percentage of participantsCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Percentage of Participants With Respiratory-Related Hospitalization15.414.5
SecondaryTime to Respiratory-Related Hospitalization

Time from randomization to first occurrence of an event of respiratory-related hospitalization was reported. Participants without an event were censored at the last known alive day, study Day 368, or the last date during the double-blind period. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Baseline up to the event of respiratory-related hospitalization (up to Week 122)
Reported as:
Median · weeks
Time to Respiratory-Related Hospitalization
weeksCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Time to Respiratory-Related HospitalizationNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Combination Therapy (Cohort B): Placebo + Pirfenidone vs Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone · Log Rank · p = 0.6815 · Hazard ratio (hr): 0.89 · 95% CI 0.52 to 1.54
SecondaryPercentage of Participants With an Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause

DLco (in mL/min/mmHg) is a measure of the gas transfer. Predicted DLco is based on sex, age, and height of a person. Percent of predicted DLco (in %) = \[(observed DLco)/(predicted DLco)\]\*100.

Time frame:
Baseline up to the event of >/=15% absolute decrease in percentage of predicted DLco or death from any cause (up to Week 122)
Reported as:
Number · percentage of participants
Percentage of Participants With an Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause
percentage of participantsMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Percentage of Participants With an Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause9.26.614.911.0
SecondaryTime to First Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause

DLco is a measure of the gas transfer. Predicted DLco is based on sex, age, and height of a person. Percent of predicted DLco (in %) = \[(observed DLco)/(predicted DLco)\]\*100. Time from randomization to first occurrence of \>/=15% absolute decrease in percentage of predicted DLco or death from any cause was reported. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Baseline up to the event of >/=15% absolute decrease in percentage of predicted DLco or death from any cause (up to Week 122)
Reported as:
Median · weeks
Time to First Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause
weeksMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Time to First Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any CauseNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Monotherapy (Cohort A): Placebo vs Monotherapy (Cohort A): Lebrikizumab · Log Rank · p = 0.5685 · Hazard ratio (hr): 0.72 · 95% CI 0.23 to 2.26
  • Combination Therapy (Cohort B): Placebo + Pirfenidone vs Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone · Log Rank · p = 0.1976 · Hazard ratio (hr): 0.68 · 95% CI 0.37 to 1.23
SecondaryPercentage of Participants With Anti-therapeutic Antibody (ATA) to Lebrikizumab

ATA to lebrikizumab was tested using a validated immunoassay. A positive ATA result was defined as one in which the presence of detectable ATAs could be confirmed by competitive binding with lebrikizumab. Percentage of participants with positive results for ATA at Baseline and at post-baseline time points were reported. Only participants who received lebrikizumab were included in the analysis.

Time frame:
Baseline and Post-Baseline (assessed at multiple time points: Weeks 4, 12, 24, 36, 52, 56, 64, 76, and at safety follow-up up to Week 122)
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-therapeutic Antibody (ATA) to Lebrikizumab
percentage of participantsMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Baseline5.31.8
Post-Baseline6.75.2
SecondaryMinimum Observed Serum Concentration (Cmin) of Lebrikizumab at Week 52

Participants who received lebrikizumab were only included in the analysis.

Time frame:
Predose (Hour 0) at Week 52
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Minimum Observed Serum Concentration (Cmin) of Lebrikizumab at Week 52
micrograms per milliliter (mcg/mL)Monotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Minimum Observed Serum Concentration (Cmin) of Lebrikizumab at Week 5229.6 ± 14.025.2 ± 12.7
SecondaryMinimum Observed Serum Concentration (Cmin) of Lebrikizumab

Participants who received lebrikizumab were only included in the analysis.

Time frame:
Predose (Hour 0) at Weeks 4, 12, 24, and 36
Reported as:
Mean · mcg/mL
Minimum Observed Serum Concentration (Cmin) of Lebrikizumab
mcg/mLMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Cmin at Week 414.0 ± 4.8614.9 ± 5.75
Cmin at Week 1224.4 ± 9.8625.0 ± 11.0
Cmin at Week 2428.5 ± 12.525.7 ± 12.4
Cmin at Week 3629.9 ± 14.125.6 ± 13.8
SecondaryElimination Half-Life (t1/2) of Lebrikizumab

Elimination half-life is the time measured for the plasma drug concentration to decrease by one-half during the elimination phase of the drug. Analysis was performed on PK-Evaluable Population. Participants who received lebrikizumab were only included in the analysis.

Time frame:
Pre-dose (Hour 0) at Weeks 1, 4, 12, 24, 36, 64, 76, 88, 104; and at 4, 12, and 18 weeks post-last dose (last dose = Week 104)
Reported as:
Mean · days
Elimination Half-Life (t1/2) of Lebrikizumab
daysMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Elimination Half-Life (t1/2) of Lebrikizumab23.5 ± 5.3621.9 ± 4.79

Adverse events

Collected over Baseline up to Week 122. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Monotherapy (Cohort A): Placebo4/76 (5.3%)19/76 (25%)70/76 (92.1%)
Monotherapy (Cohort A): Lebrikizumab4/78 (5.1%)23/78 (29.5%)73/78 (93.6%)
Combination Therapy (Cohort B): Placebo + Pirfenidone15/177 (8.5%)47/177 (26.6%)158/177 (89.3%)
Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone7/174 (4%)56/174 (32.2%)142/174 (81.6%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
EventMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders13/7611/7822/17717/174
Lower respiratory tract infectionInfections and infestations1/764/782/1771/174
PneumoniaInfections and infestations2/763/787/1777/174
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/762/781/1772/174
Respiratory tract infectionInfections and infestations1/761/783/1775/174
Coronary artery diseaseCardiac disorders2/760/782/1772/174
Pancreatitis acuteGastrointestinal disorders2/760/780/1770/174
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/761/781/1771/174
PneumomediastinumRespiratory, thoracic and mediastinal disorders2/760/780/1771/174
PneumothoraxRespiratory, thoracic and mediastinal disorders2/762/780/1771/174
Most frequent other events
Showing 10 of 57
Most frequent other events
EventMonotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + Pirfenidone
CoughRespiratory, thoracic and mediastinal disorders19/7621/7846/17733/174
NasopharyngitisInfections and infestations19/7617/7825/17731/174
Upper respiratory tract infectionInfections and infestations13/7618/7838/17731/174
DiarrhoeaGastrointestinal disorders16/7617/7823/17718/174
FatigueGeneral disorders12/7615/7822/17728/174
BronchitisInfections and infestations11/7615/7811/17717/174
DizzinessNervous system disorders10/7614/7814/17711/174
DyspnoeaRespiratory, thoracic and mediastinal disorders12/7614/7818/17713/174
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders13/7611/7810/1779/174
NauseaGastrointestinal disorders10/7610/7823/17728/174

Baseline characteristics

Analysis was performed on Intent-to-Treat (ITT) Population, which included all participants who were randomized in the study, with participants grouped according to the treatment assignment at randomization.

Age, Customized
Age, Customized(participants)Monotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + PirfenidoneTotal
From 40 to <55 years216211
From 55 to <65 years18104041109
From 65 to <75 years38449992273
>/=75 years18233239112
Sex: Female, Male
Sex: Female, Male(Participants)Monotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + PirfenidoneTotal
Female1313303793
Male6365147137412
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Monotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + PirfenidoneTotal
Hispanic or Latino96131543
Not Hispanic or Latino6468160155447
Unknown or Not Reported344415
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Monotherapy (Cohort A): PlaceboMonotherapy (Cohort A): LebrikizumabCombination Therapy (Cohort B): Placebo + PirfenidoneCombination Therapy (Cohort B): Lebrikizumab + PirfenidoneTotal
American Indian or Alaska Native11013
Asian118191553
Native Hawaiian or Other Pacific Islander10102
Black or African American00112
White6066149151426
More than one race01001
Unknown or Not Reported327618
08

Study locations

112 sites
  • University Alabama At Birmingham
    Birmingham, Alabama 35294, United States
  • Mayo Clinic- Scottsdale
    Scottsdale, Arizona 85259, United States
  • Southern Arizona Veterans Administration Healthcare Systems
    Tucson, Arizona 85723, United States
  • University of Arizona
    Tucson, Arizona 85724-5030, United States
  • UCSD Medical Center
    La Jolla, California 92093, United States
  • University of California, San Francisco
    San Francisco, California 94116, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Rocky Mountain Center For Clinical Research
    Wheat Ridge, Colorado 80033, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06520, United States
  • Research Alliance Inc
    Clearwater, Florida 33756, United States
  • Mayo Clinic-Jacksonville
    Jacksonville, Florida 32224, United States
  • University Miami
    Miami, Florida 33136, United States
  • Central Florida Pulmonary Group, PA
    Orlando, Florida 32803, United States
  • USF Tampa General Hospital
    Tampa, Florida 33606, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Piedmont Healthcare Pulmonary and Critical Care Research
    Austell, Georgia 30106, United States
  • Southeastern Lung Care
    Decatur, Georgia 30033, United States
  • University of Chicago; Pulmonary and Critical Care
    Chicago, Illinois 60637, United States
  • Loyola University Med Center
    Maywood, Illinois 60153, United States
  • Univ of Iowa Hosp & Clinics; Pulmonary
    Iowa City, Iowa 52242, United States
  • Uni of Kansas Medical Center
    Kansas, Kansas 66160, United States
  • Via Christi Hospital Inc. DBA Via Christi Research; Research Dept.
    Wichita, Kansas 67208, United States
  • Maine Medical Center -Division of Pulmomary and Critical Care Medicine
    Portland, Maine 04106, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Johns Hopkins Bayview Medical Center - Johns Hopkins Asthma & Allergy Center
    Baltimore, Maryland 21224, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • University of Minnesota Hospital & Clinic
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55902, United States
  • Cardiopulmonary Associates LLC Cardiopulmonary Research
    Chesterfield, Missouri 63017, United States
  • University of Nebraska
    Omaha, Nebraska 68198-5300, United States
  • Lovelace Scientific Resources, Inc.
    Albuquerque, New Mexico 87108, United States
  • Weill Medical College of Cornell University
    New York, New York 10021-5663, United States
  • Mt Sinai School Medical Pulmo And Critical Care Med
    New York, New York 10029, United States
  • Highland Hospital-University of Rochester Medical Center
    Rochester, New York 14620, United States
  • University of Cincinnati
    Cincinnati, Ohio 45203-0542, United States
  • Case Western Research University; University Hospitals Case Medical Center
    Cleveland, Ohio 44106-5067, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Oklahoma University Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • The Oregon Clinic.
    Portland, Oregon 97220, United States
  • Penn State University College Medical Allergy And Care Med
    Hershey, Pennsylvania 17033, United States
  • Temple Lung Center, Temple Universtiy-Of the Commomwealth System of Higher Education
    Philadelphia, Pennsylvania 19140, United States
  • University of Pittsburgh Med Cen; Dorothy P And Richard P Simmons Cen For Interstitial Lung Disease
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor College Med
    Houston, Texas 77030, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Audie Murphy Va Hospital
    San Antonio, Texas 78229, United States
  • University of Utah Health Sciences Center, Lung Health Research Center
    Salt Lake City, Utah 84108, United States
  • University Vermont College Medicine Fletcher Allen Health Care
    Colchester, Vermont 05446, United States
  • Inova Transplant Center Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Pulmonary Consultants
    Tacoma, Washington 98405, United States
  • University Wisconsin Hospitals and Clinics
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Royal Prince Alfred Hospital; Department of Respiratory Medicine
    Camperdown, New South Wales 2050, Australia
  • ST VINCENT'S HOSPITAL; Thoracic Medicine
    Darlinghurst, New South Wales 2010, Australia
  • Box Hill Hospital; Eastern Clinical Research Unit
    Box Hill, Victoria 3128, Australia
  • Alfred Hospital; Allergy Immuno Resp
    Melbourne, Victoria 3004, Australia
  • Institute for Respiratory Health Inc
    Nedlands, Western Australia 6009, Australia
  • Hospital Erasme; Neurologie
    Bruxelles, 1070, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • CHU UCL Mont-Godinne
    Mont-godinne, 5530, Belgium
  • University of British Columbia - Vancouver Coastal Health Authority
    Vancouver, British Columbia V5Z 1M9, Canada
  • Dr. Georges-L. Dumont Regional Hospital
    Moncton, New Brunswick E1G 2K5, Canada
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N4A6, Canada
  • Lawson Health Research Institute a joint venture of LHSC Research Inc and Lawson Research Institute
    London, Ontario N6C 2R5, Canada
  • Institut universitaire de cardiologie et de pneumologie de Québec (Hôpital Laval)
    Ste. Foy, Quebec G1V 4G5, Canada
  • Hopital Avicenne; Pneumologie
    Bobigny, 93000, France
  • Hopital Louis Pradel; Pneumologie
    Bron, 69677, France
  • Hopital Calmette; Pneumologie
    Lille, 59037, France
  • Hopital Bichat Claude Bernard ; Service de Pneumologie
    Paris, 75877, France
  • Hopital de Pontchaillou; Service de Pneumologie
    Rennes, 35033, France
  • Ruhrlandklinik Lungenzentrum der UNI Essen Abt.Pneumologie-Allergologie
    Essen, 45239, Germany
  • Universitätsklinikum Standort Gießen Medizinische Klinik II u. Poliklinik Innere Med./Pneumologie
    Gießen, 35392, Germany
  • LungenClinic Großhansdorf
    Großhansdorf, 22927, Germany
  • Thoraxklinik Heidelberg gGmbH
    Heidelberg, 69126, Germany
  • Fachklinik für Lungenerkrankungen
    Immenhausen, 34376, Germany
  • CPC Comprehensive Pneumology Center / Forschungsambulanz, Helmholtz Zentrum
    München, 81377, Germany
  • Ospedale Morgagni-Pierantoni; U.O. Pneumologia
    Forlì, Emilia-Romagna 47121, Italy
  • Policlinico Tor Vergata; UO Mal. Respiratorie; Centro Malattie rare polmone
    Roma, Lazio 00133, Italy
  • Ospedale San Giuseppe; U.O. di Pneumologia
    Milano, Lombardia 20123, Italy
  • A.O. Universitaria San Luigi Gonzaga di Orbassano; Ambulatorio per le Malattie Rare del Polmone
    Orbassano (TO), Piemonte 10043, Italy
  • A.O.U. Policlinico Vittorio Emanuele; Centro per la cura delle Malattie Rare del Polmone
    Catania, Sicilia 95123, Italy
  • A.O. Univ. Senese Policlinico S. Maria alle Scotte; UOC Malattie Resepiratorie e Trapianto Polmonare
    Siena, Toscana 53100, Italy
  • Kanagawa Cardiovascular and Respiratory Center; Respiratory Medicine
    Kanagawa, 236-0051, Japan
  • Kinki-Chuo Chest Medical Center
    Osaka, 591-8555, Japan
  • Tosei General Hospital
    Seto-shi, 489-8642, Japan
  • Hospital General Del Estado De Sonora "Dr. Ernesto Ramos Bours"; Servicio De Neumologia
    Hermosillo, 83000, Mexico
  • Instituto Nacional De Enfermedades Respiratorias;Unidad de Investigación
    Mexico City, 14080, Mexico
  • Universidad Autonoma De Nuevo Leon, Hospital Universitario Doctor Jose Eleuterio Gonzalez
    Monterrey, 64460, Mexico
  • Unidad de Investigacion Clinica En Medicina (Udicem) S.C.
    Monterrey, 64718, Mexico
  • Clinica San Pablo
    Lima, Lima 33, Peru
  • Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional
    Lima, Lima 41, Peru
  • Clinica San Borja; NEUMOCARE
    Lima, Lima 41, Peru
  • Uniwersytecki Szpital Kliniczny Nr 1 im.N.Barlickiego Oddzial Kliniczny Pneumonologii i Alergologii
    Lodz, 90-153, Poland
  • Ms Clinsearch Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej
    Lublin, 20-064, Poland
  • Klinika Pulmonologii, Alergologii i Onkologii Pulmonologicznej Uniwersytet Medyczny w Poznaniu
    Poznan, 60-569, Poland
  • Instytut Gruzlicy i Chorob Płuc
    Warszawa, 01-138, Poland
  • Klinika Chorob Pluc i Gruzlicy w Zabrzu; Slaski Uniwersytet Medyczny
    Zabrze, 41-803, Poland

Showing the first 100 of 112 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Allen RJ, Stockwell A, Oldham JM, Guillen-Guio B, Schwartz DA, Maher TM, Flores C, Noth I, Yaspan BL, Jenkins RG, Wain LV; International IPF Genetics Consortium. Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. Thorax. 2022 Aug;77(8):829-833. doi: 10.1136/thoraxjnl-2021-218577. Epub 2022 Jun 10. PubMed 35688625 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Jul 2017, 45 months.

Results were first posted in Aug 2018, 1 year after primary completion.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 45 months is above that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2013
First posted
Jun 7, 2013
StartActual
Oct 13, 2013
Primary completionActual
Jul 28, 2017
CompletionActual
Nov 6, 2017
Results first posted
Aug 24, 2018
Last update
Aug 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01872689
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 7, 2013
Start date
Oct 13, 2013
Primary completion
Jul 28, 2017
Completion
Nov 6, 2017
Results posted
Aug 24, 2018
Last update
Aug 24, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lebrikizumab · Pirfenidone

Start the discussion